Alibaba Group Holding Ltd. is selling assets from medical devices to drugs for HK$10.6 billion ($1.4 billion) to a Hong Kong-listed unit that it’ll take control of and turn into its main healthcare arm.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
